Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

N-acetylcysteine modulates the cytotoxic effects of Paclitaxel.

Lyle PA, Mitsopoulos P, Suntres ZE.

Chemotherapy. 2011;57(4):298-304. doi: 10.1159/000329510. Epub 2011 Jul 20.

PMID:
21778718
2.

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.

Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E, Fyhrquist F, Hille DA, Ibsen H, Lyle PA, Berg K, Sandberg M, Sethi AA, Wong PH, Os I.

Pharmacogenet Genomics. 2010 Feb;20(2):77-85. doi: 10.1097/FPC.0b013e328333f70b.

PMID:
20065889
3.

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.

Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.

Blood Press. 2009;18(6):348-61. doi: 10.3109/08037050903460590.

PMID:
20001655
4.

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.

Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Simone G, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Lyle PA, Nieminen MS, Omvik P, Oparil S, Wedel H.

J Hypertens. 2009 Mar;27(3):567-74. doi: 10.1097/HJH.0b013e32831daf96.

PMID:
19262226
5.

The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.

Wachtell K, Devereux RB, Lyle PA, Okin PM, Gerdts E.

Ther Adv Cardiovasc Dis. 2008 Dec;2(6):507-13. doi: 10.1177/1753944708093846. Epub 2008 Aug 21. Review.

PMID:
19124445
6.

A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.

Oparil S, Abate N, Chen E, Creager MA, Galet V, Jia G, Julius S, Lerman A, Lyle PA, Pool J, Tershakovec AM.

Curr Med Res Opin. 2008 Apr;24(4):1101-14. doi: 10.1185/030079908X280716 . Epub 2008 Mar 6.

PMID:
18328120
7.

Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.

Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, Hille DA, Lyle PA, Okin PM, Dahlöf B, Oparil S.

Hypertension. 2008 Apr;51(4):1103-8. doi: 10.1161/HYPERTENSIONAHA.107.105296. Epub 2008 Feb 7.

PMID:
18259029
8.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM.

J Am Soc Nephrol. 2008 Apr;19(4):771-9. doi: 10.1681/ASN.2007050582. Epub 2008 Jan 16.

9.

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.

Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD.

Kidney Int. 2008 Mar;73(5):630-6. Epub 2007 Dec 19.

10.

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.

PMID:
18070995
11.

The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.

Fossum E, Gleim GW, Kjeldsen SE, Kizer JR, Julius S, Devereux RB, Brady WE, Hille DA, Lyle PA, Dahlöf B.

J Intern Med. 2007 Oct;262(4):439-48.

12.

Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).

Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B.

Am J Cardiol. 2007 Sep 1;100(5):855-9. Epub 2007 Jul 2.

PMID:
17719333
13.

Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.

Kjeldsen SE, Lyle PA, Kizer JR, Oparil S, Høieggen A, Os I.

Vasc Health Risk Manag. 2007;3(3):299-305. Review.

14.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators.

Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17.

15.

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.

de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB.

J Hum Hypertens. 2007 Aug;21(8):625-32. Epub 2007 May 3.

PMID:
17476291
16.

Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?

Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM.

Blood Press. 2007;16(1):6-12.

PMID:
17453746
18.
19.

The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.

Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS.

J Hum Hypertens. 2006 Jun;20(6):460-4. No abstract available.

PMID:
16572193
20.

Losartan: lessons learned from the RENAAL study.

Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM.

Expert Opin Pharmacother. 2006 Apr;7(5):623-30. Review.

PMID:
16553578
21.

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA.

Diabetes Care. 2006 Mar;29(3):595-600.

PMID:
16505512
22.

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.

Am J Cardiol. 2005 Dec 1;96(11):1530-6. Epub 2005 Oct 17.

PMID:
16310435
23.

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, Oparil S, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H.

Expert Opin Emerg Drugs. 2005 Nov;10(4):729-45. Review.

PMID:
16262560
24.

Kidney disease and cardiovascular disease: implications of dyslipidemia.

Keane WF, Lyle PA.

Cardiol Clin. 2005 Aug;23(3):363-72. Review.

PMID:
16084284
25.

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.

Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.

Hypertension. 2005 Apr;45(4):580-5.

PMID:
15790960
26.

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.

Kjeldsen SE, Lyle PA, Kizer JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group.

J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8.

27.
28.

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.

Kidney Int Suppl. 2004 Nov;(92):S115-7. Review.

29.

Hypertension and medical informatics.

McBride W, Ferrario C, Lyle PA.

J Natl Med Assoc. 2003 Nov;95(11):1048-56. Review.

30.

An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.

Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS, Snapinn SM.

Clin Ther. 2003 Apr;25(4):1186-99.

PMID:
12809965
31.

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.

PMID:
12612946
32.

First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Investigators.

Lang RM, DiBianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ.

Am Heart J. 1994 Sep;128(3):551-6.

PMID:
8074019
33.

Applications of spectral hole burning spectroscopies to antenna and reaction center complexes.

Reddy NR, Lyle PA, Small GJ.

Photosynth Res. 1992 Mar;31(3):167-94. doi: 10.1007/BF00035536.

PMID:
24408059
34.

Synthesis and evaluation of some nitrobenzenesulfonamides containing nitroisopropyl and (ureidooxy)methyl groups as novel hypoxic cell selective cytotoxic agents.

Saari WS, Schwering JE, Lyle PA, Engelhardt EL, Sartorelli AC, Rockwell S.

J Med Chem. 1991 Oct;34(10):3132-8.

PMID:
1920362
35.

Cyclization-activated prodrugs. Basic esters of 5-bromo-2'-deoxyuridine.

Saari WS, Schwering JE, Lyle PA, Smith SJ, Engelhardt EL.

J Med Chem. 1990 Sep;33(9):2590-5.

PMID:
2391697
36.

Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.

Thompson WJ, Anderson PS, Britcher SF, Lyle TA, Thies JE, Magill CA, Varga SL, Schwering JE, Lyle PA, Christy ME, et al.

J Med Chem. 1990 Feb;33(2):789-808.

PMID:
1688947
37.

Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole.

Saari WS, Schwering JE, Lyle PA, Smith SJ, Engelhardt EL.

J Med Chem. 1990 Jan;33(1):97-101.

PMID:
2296038
38.

Spectral hole burning of the primary electron donor state of Photosystem I.

Gillie JK, Lyle PA, Small GJ, Golbeck JH.

Photosynth Res. 1989 Dec;22(3):233-46. doi: 10.1007/BF00048302.

PMID:
24424813
39.

Safety and tolerability of lisinopril in older hypertensive patients.

Rush JE, Lyle PA.

Am J Med. 1988 Sep 23;85(3B):55-9.

PMID:
2844089
40.

Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors.

Ponticello GS, Freedman MB, Habecker CN, Lyle PA, Schwam H, Varga SL, Christy ME, Randall WC, Baldwin JJ.

J Med Chem. 1987 Apr;30(4):591-7.

PMID:
3560154
41.

Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.

Baldwin JJ, Christy ME, Denny GH, Habecker CN, Freedman MB, Lyle PA, Ponticello GS, Varga SL, Gross DM, Sweet CS.

J Med Chem. 1986 Jun;29(6):1065-80.

PMID:
2872332

Supplemental Content

Support Center